DelveInsight’s, “Oropharyngeal Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oropharyngeal Cancer pipeline landscape. It covers the Oropharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Oropharyngeal Cancer Emerging drugs, the Oropharyngeal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Oropharyngeal Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Oropharyngeal Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Oropharyngeal Cancer clinical trials studies, Oropharyngeal Cancer NDA approvals (if any), and product development activities comprising the technology, Oropharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Oropharyngeal Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Oropharyngeal Cancer Pipeline landscape @ Oropharyngeal Cancer Pipeline Outlook Report
Oropharyngeal Cancer Overview
Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal Cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs.
Oropharyngeal Cancer Emerging Drugs Profile
Cisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells’ genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.
ISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.
Oropharyngeal Cancer Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Oropharyngeal Cancer. The companies which have their Oropharyngeal Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.
Oropharyngeal Cancer Pipeline
Phases
Route of Administration
Find out more about the Oropharyngeal Cancer Pipeline Segmentation, Therapeutics Assessment, and Oropharyngeal Cancer Emerging Drugs @ Oropharyngeal Cancer Treatment Landscape
Scope of the Oropharyngeal Cancer Pipeline Report
Got Queries? Find out the related information on Oropharyngeal Cancer Mergers and acquisitions, Oropharyngeal Cancer Licensing Activities @ Oropharyngeal Cancer Recent Trends, and Future Perspectives
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/